Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Am Vet Med Assoc ; 260(2): 234-243, 2021 11 30.
Artigo em Inglês | MEDLINE | ID: mdl-34851850

RESUMO

OBJECTIVE: To provide updated information on the distribution of histopathologic types of primary pulmonary neoplasia in dogs and evaluate the effect of postoperative adjuvant chemotherapy in dogs with pulmonary carcinoma. ANIMALS: 340 dogs. PROCEDURES: Medical records of dogs that underwent lung lobectomy for removal of a primary pulmonary mass were reviewed, and histopathologic type of lesions was determined. The canine lung carcinoma stage classification system was used to determine clinical stage for dogs with pulmonary carcinoma. RESULTS: Pulmonary carcinoma was the most frequently encountered tumor type (296/340 [87.1%]), followed by sarcoma (26 [7.6%]), adenoma (11 [3.2%]), and pulmonary neuroendocrine tumor (5 [1.5%]); there was also 1 plasmacytoma and 1 carcinosarcoma. Twenty (5.9%) sarcomas were classified as primary pulmonary histiocytic sarcoma. There was a significant difference in median survival time between dogs with pulmonary carcinomas (399 days), dogs with histiocytic sarcomas (300 days), and dogs with neuroendocrine tumors (498 days). When dogs with pulmonary carcinomas were grouped on the basis of clinical stage, there were no significant differences in median survival time between dogs that did and did not receive adjuvant chemotherapy. CLINICAL RELEVANCE: Results indicated that pulmonary carcinoma is the most common cause of primary pulmonary neoplasia in dogs; however, nonepithelial tumors can occur. Survival times were significantly different between dogs with pulmonary carcinoma, histiocytic sarcoma, and neuroendocrine tumor, emphasizing the importance of recognizing the relative incidence of these various histologic diagnoses. The therapeutic effect of adjuvant chemotherapy in dogs with pulmonary carcinoma remains unclear and warrants further investigation.


Assuntos
Doenças do Cão , Sarcoma Histiocítico , Neoplasias Pulmonares , Animais , Doenças do Cão/diagnóstico , Doenças do Cão/cirurgia , Cães , Sarcoma Histiocítico/patologia , Sarcoma Histiocítico/terapia , Sarcoma Histiocítico/veterinária , Pulmão/patologia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/veterinária , Estudos Retrospectivos
2.
Vet Comp Oncol ; 19(4): 671-677, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34240790

RESUMO

Accurate tumour staging has a profound impact on the care and prognosis of oncologic patients. Due to the presence of multiple lymph nodes (LNs) in the mandibular lymphocentrum, clinicians may not know which specific LN they are sampling during routine fine needle aspirations, which introduces a source of uncertainty in accurately determining patient clinical stage. The objective of this cadaveric study was to determine the success of targeting specific mandibular LNs by palpation alone, verified by computed tomography (CT). A 1.5-inch, 22-gauge needle was inserted into the targeted LN (selected by drawing with the equal sample sizes of the left/right mandibular lymphocentrum and the lateral/medial node) and success was evaluated by CT images in transverse, sagittal and dorsal views. The overall success rate of inserting the needle into the targeted LN was 55.9%. One variable was significantly associated with successful needle insertion: lateral (vs. medial) LN location (p = .019). In addition, the distance from the LN to the ventral skin surface in the successful group appeared to be shorter compared to the unsuccessful group (3.37 mm [1.55-6.46] vs. 4.9 mm [1.57-17.79], p = .066). These findings suggest that physical accessibility of the LN is the most important factor for successful needle insertion using palpation. Palpation-based sampling of specific mandibular LNs is often inaccurate and if targeted sampling of a particular LN is required, additional methods should be used to guide accurate sample acquisition.


Assuntos
Biópsia por Agulha Fina , Doenças do Cão , Estadiamento de Neoplasias/veterinária , Animais , Biópsia por Agulha Fina/veterinária , Cadáver , Doenças do Cão/diagnóstico por imagem , Cães , Linfonodos/diagnóstico por imagem
3.
Vet Comp Oncol ; 18(4): 580-589, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32103587

RESUMO

Low-grade canine cutaneous mast cell tumour (cMCT) with metastasis at the time of treatment is uncommonly reported, with few studies focusing on this specific clinical entity. The specific objective of this study was to systematically review the veterinary literature and perform a meta-analysis summarizing the clinical presentation, treatments reported and clinical outcomes from dogs with histologically low-grade cMCT and metastasis present at initial treatment. A total of 980 studies were screened with eight publications providing data on 121 dogs ultimately included. The most common treatments were surgery with adjuvant chemotherapy in 83/121 (69%) dogs; combined surgery, radiation and chemotherapy in 17/121 (14%) dogs; chemotherapy alone in 12/121 (10%) dogs and surgery alone in 7/121 (6%) dogs. Dogs with distant metastasis (n = 22) experienced significantly shorter survival compared with those with regional lymph node (RLN) metastasis (n = 99; median 194 vs 637 days; P < .01). Two variables were significantly associated with increased risk of death: presence of distant (vs RLN) metastasis (hazard ratio = 2.60; P < .01) and not receiving surgery as a component of treatment (hazard ratio = 3.79; P < .01). Risk of bias was judged to be low in terms of selection and performance bias but high in terms of detection and exclusion bias. In conclusion, dogs with cMCT and RLN metastasis can be expected to live significantly longer than those with distant metastasis, and surgery appears to have a role in extending survival of metastatic low-grade cMCT.


Assuntos
Doenças do Cão , Sarcoma de Mastócitos/veterinária , Mastocitose Cutânea/veterinária , Animais , Doenças do Cão/mortalidade , Doenças do Cão/patologia , Doenças do Cão/terapia , Cães , Metástase Linfática/patologia , Metástase Linfática/terapia , Mastócitos/patologia , Sarcoma de Mastócitos/mortalidade , Sarcoma de Mastócitos/patologia , Sarcoma de Mastócitos/terapia , Mastocitose Cutânea/mortalidade , Mastocitose Cutânea/patologia , Mastocitose Cutânea/terapia , Estadiamento de Neoplasias
4.
BMC Complement Altern Med ; 17(1): 428, 2017 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-28851336

RESUMO

BACKGROUND: In immunocompromised patients, human cytomegalovirus (HCMV) infection can lead to severe, life-threatening diseases, such as pneumonitis, hepatitis, gastrointestinal tract disease, and retinitis. We previously reported that a 70% ethanol extract of Elaeocarpus sylvestris leaves (ESE) inhibits human cytomegalovirus (HCMV) replication in vitro. In the present study, we determined the solvent fraction of ESE that inhibits HCMV replication using activity-guided fractionation. METHODS: Activity-guided fractionation of ESE was performed to determine the solvent fraction that inhibits HCMV replication. Effects of solvent fractions on HCMV lytic gene expression and major immediate-early (MIE) enhancer/promoter activity were further investigated. RESULTS: Among the solvent fractions tested, the EtOAc fraction of ESE markedly reduced HCMV lytic gene expression and viral replication in vitro without exerting significant cytotoxic effects against human foreskin fibroblasts (HFF). Furthermore, the EtOAc fraction negatively affected HCMV MIE enhancer/promoter activity. CONCLUSION: Our data collectively indicate that the EtOAc fraction of ESE contains active constituents that inhibit HCMV MIE enhancer/promoter activity and viral replication. The EtOAc fraction of ESE is a good source of novel drug candidates for treatment of HCMV-associated diseases.


Assuntos
Antivirais/farmacologia , Citomegalovirus/efeitos dos fármacos , Citomegalovirus/fisiologia , Elaeocarpaceae/química , Extratos Vegetais/farmacologia , Replicação Viral/efeitos dos fármacos , Antivirais/isolamento & purificação , Citomegalovirus/genética , Infecções por Citomegalovirus/virologia , Genes Precoces , Humanos , Extratos Vegetais/isolamento & purificação , Proteínas Virais/genética , Proteínas Virais/metabolismo
5.
Antiviral Res ; 144: 266-272, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28668556

RESUMO

The aim of this study was to establish the effect of a 70% ethanol extract of Elaeocarpus sylvestris (ESE) on varicella-zoster virus (VZV) replication and identify the specific bioactive component(s) underlying its activity. ESE induced a significant reduction in replication of the clinical strain of VZV. Activity-guided fractionation indicated that the ethyl acetate (EtOAc) fraction of ESE contains the active compound(s) inhibiting VZV replication. High-Performance Liquid Chromatography coupled to Electrospray Ionization Quadrupole Time-of-Flight Mass Spectrometry (HPLC-Q-TOF-MS/MS) analysis of the EtOAc fraction of ESE facilitated the identification of 13 chemical components. Among these, 1,2,3,4,6-penta-O-galloyl-ß-D-glucose (PGG) markedly suppressed VZV-induced c-Jun N-terminal kinase (JNK) activation, expression of viral immediate-early 62 (IE62) protein and VZV replication. Our results collectively support the utility of PGG as a potential candidate anti-viral drug to treat VZV-associated diseases.


Assuntos
Elaeocarpaceae/química , Herpesvirus Humano 3/efeitos dos fármacos , Taninos Hidrolisáveis/farmacologia , Extratos Vegetais/química , Replicação Viral/efeitos dos fármacos , Células Cultivadas , Cromatografia Líquida de Alta Pressão , Herpesvirus Humano 3/fisiologia , Humanos , Taninos Hidrolisáveis/isolamento & purificação , Proteínas Imediatamente Precoces/análise , Proteínas Quinases JNK Ativadas por Mitógeno/análise , Espectrometria de Massas por Ionização por Electrospray , Transativadores/análise , Proteínas do Envelope Viral/análise
6.
Mol Med Rep ; 15(6): 3847-3851, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28393250

RESUMO

Varicella­zoster virus (VZV), a ubiquitous human α­herpesvirus, is the causative agent of chickenpox and shingles. In the present study, we investigated the antiviral activity of a 70% ethanol extract of Lysimachia mauritiana (LME) against VZV. LME strongly interfered with the replication of both laboratory and clinical strains of VZV without affecting the viability of MRC­5 cells. Moreover, LME treatment suppressed the expression of an essential viral transactivator, immediate­early 62 protein (IE62), in addition to other lytic genes in the later phases of viral replication. The finding that LME exerts potent inhibitory effects on VZV gene expression and replication supports its potential utility as a therapeutic anti­viral agent.


Assuntos
Antivirais/farmacologia , Herpesvirus Humano 3/efeitos dos fármacos , Herpesvirus Humano 3/fisiologia , Extratos Vegetais/farmacologia , Primulaceae/química , Replicação Viral/efeitos dos fármacos , Linhagem Celular Tumoral , Células Cultivadas , Relação Dose-Resposta a Droga , Regulação Viral da Expressão Gênica/efeitos dos fármacos , Humanos
7.
J Vet Med Sci ; 78(12): 1811-1818, 2017 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-27647656

RESUMO

The purpose of this study was to investigate the protein expression pattern and the in vivo trichogenicity of dermal papilla-like tissues (DPLTs) made from canine adipose-derived mesenchymal stem cells (ASCs) in athymic nude mice. Canine ASCs were isolated and cultured from adipose tissue, and differentiation was induced by culturing ASCs in dermal papilla forming media. DPLTs were embedded in collagen gel, and their structural characteristics and protein expression were evaluated by hematoxylin and eosin stain and immunohistochemistry. Athymic nude mice were divided into two groups (control and DPLTs groups), and DPLTs were injected in skin wounds of mice in the DPLTs group. The trichogenicity of DPLTs was assessed by gross and histological evaluations for 30 days. The fate and the growth factor-secretion effect of DPLTs were evaluated by immunohistochemistry and Western blotting. DPLTs have a compact aggregated structure, form extracellular matrix and highly express the protein specific for dermal papillae, including ALP and versican. New hair follicle formation was remarkable in nude mice of the DPLTs group in gross findings and H&E stain. Vascularization was increased in the DPLTs group, which was the effect of vascular endothelial growth factor secreted by DPLTs in vitro and in vivo. These data suggest that engineered canine DPLTs have characteristics of dermal papillae and have a positive effect on hair regeneration by secreting growth factors.


Assuntos
Derme/fisiologia , Folículo Piloso/fisiologia , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/fisiologia , Tecido Adiposo/citologia , Animais , Diferenciação Celular , Derme/citologia , Cães , Feminino , Camundongos , Camundongos Nus , Regeneração , Pele/lesões , Fator A de Crescimento do Endotélio Vascular/metabolismo
8.
J Biomed Mater Res B Appl Biomater ; 101(6): 919-28, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23529895

RESUMO

This study investigates the feasibility of using an adipose-derived mesenchymal stem cell (ASC)-seeded acellular dermal matrix (ADM) along with low-level laser therapy (LLLT) to repair bone defect in athymic nude mice. Critical-sized calvarial defects were treated either with ADM, ADM/LLLT, ADM/ASCs, or ADM/ASCs/LLLT. In micro-computed tomography scans, the ADM/ASCs and the ADM/ASCs/LLLT groups showed remarkable bone formation after 14 days. Additionally, bone regeneration in the ADM/ASCs/LLLT group was obvious at 28 days, but in the ADM/ASCs group at 56 days. Bone mineral density and bone tissue volume in the ADM/ASCs/LLLT group significantly increased after 7 days, but in the ADM/ASCs group after 14 days. Histological analysis revealed that the defects were repaired in the ADM/ASCs and the ADM/ASCs/LLLT group, while the defects in the ADM and the ADM/LLLT groups exhibited few bone islands at 28 and 56 days. The successful seeding of ASCs onto ADM was confirmed, and LLLT enhanced the proliferation and the survival of ASCs at 14 days. Our results indicate that ASC-seeded grafts promote bone regeneration, and the application of LLLT on ASC-seeded ADM results in rapid bone formation. The implantation of an ASC-seeded ADM combined with LLLT may be used effectively for bone regeneration.


Assuntos
Terapia com Luz de Baixa Intensidade , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/efeitos da radiação , Osteogênese/efeitos da radiação , Alicerces Teciduais , Derme Acelular , Adipócitos/citologia , Adipócitos/metabolismo , Adipócitos/efeitos da radiação , Animais , Biomarcadores/metabolismo , Regeneração Óssea/efeitos da radiação , Diferenciação Celular/efeitos da radiação , Células Cultivadas , Cães , Humanos , Masculino , Teste de Materiais , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/metabolismo , Camundongos , Camundongos Nus , Microscopia Eletrônica de Varredura , Crânio/patologia , Crânio/efeitos da radiação , Crânio/cirurgia , Engenharia Tecidual , Alicerces Teciduais/química , Microtomografia por Raio-X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...